Sponsor Pipeline

Shu Wang Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
8
Active Trials
8
Recruiting
3
Disease Areas
Active Trials by Phase
Not specified
8
Active Trials
NCT IDTitleConditionStatus
Not specified
NCT06693024 Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer HER2-positive Breast Cancer Recruiting
NCT06693037 Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant… HER2-positive Breast Cancer Recruiting
NCT06700369 De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2… HER2-positive Breast Cancer Recruiting
NCT06700382 Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for… Triple Negative Breast Cancer Recruiting
NCT06711055 Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative… HER2-positive Breast Cancer Recruiting
NCT06711068 Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast… HER2-positive Breast Cancer Recruiting
NCT06722599 Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk… HER2-positive Breast Cancer Recruiting
NCT06722612 Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node… HER2-positive Breast Cancer Recruiting
Disease Areas
Get alerts when Shu Wang's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free